secwatch.observer — SEC 8-K summary
======================================

Issuer:     Phathom Pharmaceuticals, Inc. (PHAT)
CIK:        0001783183
Form:       8-K
Filed at:   2023-11-28T23:59:59+00:00
Accession:  0001193125-23-283719
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Phathom launches VOQUEZNA for erosive GERD; H. pylori regimens expected mid-Dec.
--------------------------------------------------------------------------------

- VOQUEZNA (vonoprazan) now available in 30-count bottles for erosive GERD treatment and heartburn relief.
- Phase 3 trial: 93% healing rate at Week 8 with VOQUEZNA 20mg vs 85% for lansoprazole 30mg.
- VOQUEZNA 10mg superior to lansoprazole 15mg at maintaining healing at 6 months (79% vs 72%).
- No mealtime dosing required; prescriptions fillable at major retail pharmacies and via BlinkRx.
- VOQUEZNA TRIPLE PAK and DUAL PAK for H. pylori expected commercially by mid-December 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1783183/000119312523283719/0001193125-23-283719-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1783183/000119312523283719/d573061d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-283719

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer